Ensign Peak Advisors
PRLD icon

Ensign Peak Advisors’s Prelude Therapeutics PRLD Stock Holding History

Ensign Peak Advisors’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8,080
Closed -$42K – 2345
2022
Q2 		$42K Hold
8,080
– – ﹤0.01% 2083
2022
Q1 		$56K Hold
8,080
– – ﹤0.01% 2114
2021
Q4 		$101K Buy
+8,080
New +$131K ﹤0.01% 2059
2021
Q2 		– Sell
-17,498
Closed -$758K – 1848
2021
Q1 		$758K Buy
+17,498
New +$1.16M ﹤0.01% 1505

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ensign Peak Advisors's PRLD Position: Q3 2022 in Review

Ensign Peak Advisors sold out of Prelude Therapeutics (PRLD) in Q3 2022, closing a stake of 8,080 shares — an estimated $42K sold.

Ensign Peak Advisors first reported a position in PRLD in Q1 2021 and held it in 4 quarters. The position peaked at $758K in Q1 2021. 53 funds tracked by Wall St. Rank hold PRLD as of Q3 2022.

  • Ensign Peak Advisors reported no remaining Prelude Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 8,080 Prelude Therapeutics shares in Q3 2022, an estimated $42K.
  • Ensign Peak Advisors first reported a position in Prelude Therapeutics in Q1 2021 and held it in 4 quarters.
  • Ensign Peak Advisors's Prelude Therapeutics position peaked at $758K in Q1 2021.
  • 53 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2022.

Based on Ensign Peak Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.